Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study
Open accessAbstract
PURPOSE: To evaluate and compare the therapeutic efficacy of quetiapine in bipolar I and II depression patients in the clinical setting. PATIENTS AND METHODS: This was an 8-week, multicenter, open-label, observational study for bipolar depression. The dosage of quetiapine was flexible, and concomitant medications were permitted on clinician's judgments. A total of 1097 patients were enrolled, and 764 bipolar depression patients who exhibited good therapeutic compliance (>75% compliance rate) were analyzed. RESULTS: Clinical Global Impression - Bipolar scale and Montgomery-Asberg Depression Rating Scale scores were significantly improved at weeks four and eight compared with the baseline scores. At the end of the 8-week study, the response rate was 58.9%, and the remission rate was 42.1%. However, there were no significant differences in the response and remission rates between bipolar I and II disorder (BD-I and BD-II) patients (response rate 60.1% versus 56.3%; remission rate 44.5% versus 37.0%). Montgomery-Asberg Depression Rating Scale score at baseline (β = 0.612, P < 0.001), duration of current episode (β = -0.152, P = 0.001), and presence of remission on previous episode (β = 0.111, P = 0.012) were significantly associated with improvements in depressive symptoms. Fatigue (16.0%), somnolence (14.9%), and manic/hypomanic switching (0.6% at week four, 0.3% at week eight) were observed throughout the study period. CONCLUSION: The results of this study suggest that quetiapine improves depressive symptoms in BD-I and BD-II patients with a minimal incidence of manic switching. The therapeutic efficacy of quetiapine increased with time. Quetiapine could be an effective and safe modality for the treatment of BD-I and BD-II.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Open-label studies suggest efficacy for adjunctive quetiapine in acute bipolar II depression.
“Finally, open‐label studies also suggest efficacy for adjunctive quetiapine (level 4).441, 442”
From Canadian Network for Mood and Anxiety Treatments ( <scp>CANMAT</scp> ) and International Society for Bipolar Disorders ( <scp>ISBD</scp> ) 2018 guidelines for the management of patients with bipolar disorder (2018) · cites this paper as [441]
The Conclusion reports improvement in bipolar II depression during eight weeks of quetiapine treatment. The Results (p. not provided) show that other psychotropic drugs were often coadministered, including in bipolar II patients. But this open-label observational study did not establish the efficacy of quetiapine specifically as an adjunct rather than as part of treatment that sometimes included other drugs. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · see citing works
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589 · see citing works
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106 · see citing works
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978 · see citing works
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908 · see citing works
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · see citing works
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559 · see citing works
The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.
Sachs, G. S., PRINTZ, D. J., Kahn, D. A., Carpenter, D. P., & Docherty, J. P. (2000) · PubMed · Cited by 394 · see citing works
Young, A. H., McElroy, S. L., Bauer, M., Philips, N., Chang, W., Olausson, B., Paulsson, B., Brecher, M., & EMBOLDEN I (Trial 001) Investigators (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04995gre · Cited by 390 · see citing works
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388 · see citing works
Bowden, C. L., Grunze, H., Mullen, J., Brecher, M., Paulsson, B., Jones, M., Vågerö, M., & Svensson, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0116 · Cited by 376 · see citing works
Clinical Factors Associated With Treatment Noncompliance in Euthymic Bipolar Patients
Colom, F., Vieta, E., Martínez‐Arán, A., Reinares, M., Benabarre, A., & Gastó, C. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0802 · Cited by 340 · see citing works
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W. H., Maser, J. D., Rice, J. P., Solomon, D. A., & Keller, M. B. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00324-5 · Cited by 339 · see citing works
Demographic and Clinical Characteristics of Individuals in a Bipolar Disorder Case Registry
Kupfer, D. J., Frank, E., Grochocinski, V. J., Cluss, P. A., Houck, P. R., & Stapf, D. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0206 · Cited by 294 · see citing works
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S. V., MacQueen, G., McIntyre, R. S., Sharma, V., Beaulieu, S., & for CANMAT guidelines group (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00432.x · Cited by 264 · see citing works
Sachs, G. S., Sanchez, R., Marcus, R. N., Stock, E. G., McQuade, R. D., Carson, W. H., Abou-Gharbia, N., Impellizzeri, C., Kaplita, S., Rollin, L., et al. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106059693 · Cited by 245 · see citing works
McIntyre, R. S., Brecher, M., Paulsson, B., Huizar, K., & Mullen, J. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.02.006 · Cited by 226 · see citing works
Improving treatment adherence in bipolar disorder through psychoeducation.
Vieta, E. (2005) · PubMed · Cited by 127 · see citing works
Adherence to Lithium Prophylaxis: I. Clinical Predictors and Patient's Reasons for Nonadherence
Maarbjerg, K., Aagaard, J., & Vestergaard, P. (1988) · Pharmacopsychiatry · doi:10.1055/s-2007-1014662 · Cited by 89 · see citing works
Differences in outcome of DSM‐IV bipolar I and II disorders
Mantere, O., Suominen, K. H., Valtonen, H. M., Arvilommi, P., Leppämäki, S., Melartin, T. K., & Isometsä, E. T. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00502.x · Cited by 84 · see citing works
Efficacy of Quetiapine and Risperidone Against Depressive Symptoms in Outpatients With Psychosis
Sajatovic, M., Mullen, J. A., & Sweitzer, D. E. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1211 · Cited by 83 · see citing works
Role of risperidone in bipolar II: an open 6-month study
Vieta, E., Gastó, C., Colom, F., Reinares, M., Martínez‐Arán, A., Benabarre, A., & Akiskal, H. S. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00435-9 · Cited by 79 · see citing works
Shastry, B. S. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2004.10.007 · Cited by 51 · see citing works
Non‐adherence in psychiatric disorders: misbehaviour or clinical feature?
Colom, F., & Vieta, E. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.1e003.x · Cited by 48 · see citing works
Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders.
Montgomery, S. (2002) · PubMed · Cited by 35 · see citing works
Bipolar depression: the role of atypical antipsychotics
Post, R. M., & Calabrese, J. R. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.6.s27 · Cited by 14 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [1]American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision: DSM-IV-TR® Washington, DC American Psychiatric Association 2000
Cited by
Sorted by citations
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · see citing works
- Authors
- Jeong, J.-H., Bahk, W.-M., Woo, Seo, Hong, Jon, Min, & Yoon
- Affiliations
- Catholic University of Korea (KR)
- Hallym University (KR)
- Chung-Ang University (KR)
- Corresponding author
- Bahk, Won-Myong
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2013-02
- Volume
- 9
- Pages
- 197
- ISSN
- 1176-6328 (ISSN-L)
- PMC
- PMC3575218
- OpenAlex
- W1978587895
- Cited by
- 9
- References
- 26
- Citations by year
- 2021: 1 · 2020: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 4
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- quetiapine, bipolar depression, bipolar I disorder, bipolar II disorder, atypical antipsychotics, antidepressant efficacy, fatigue, sleepiness, predictors of treatment response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
